Tags

Type your tag names separated by a space and hit enter

Product of natural evolution (SARS, MERS, and SARS-CoV-2); deadly diseases, from SARS to SARS-CoV-2.
Hum Vaccin Immunother. 2021 01 02; 17(1):62-83.HV

Abstract

SARS-CoV-2, the virus causing COVID-19, is a single-stranded RNA virus belonging to the order Nidovirales, family Coronaviridae, and subfamily Coronavirinae. SARS-CoV-2 entry to cellsis initiated by the binding of the viral spike protein (S) to its cellular receptor. The roles of S protein in receptor binding and membrane fusion makes it a prominent target for vaccine development. SARS-CoV-2 genome sequence analysis has shown that this virus belongs to the beta-coronavirus genus, which includes Bat SARS-like coronavirus, SARS-CoV and MERS-CoV. A vaccine should induce a balanced immune response to elicit protective immunity. In this review, we compare and contrast these three important CoV diseases and how they inform on vaccine development.

Links

PMC Free PDF

Authors+Show Affiliations

Shahrajabian MH
Biotechnology Research Institute, Chinese Academy of Agricultural Sciences , Beijing, China.
Sun W
Biotechnology Research Institute, Chinese Academy of Agricultural Sciences , Beijing, China.
Cheng Q
Biotechnology Research Institute, Chinese Academy of Agricultural Sciences , Beijing, China. College of Life Sciences, Hebei Agricultural University , Baoding, Hebei, China. Global Alliance of HeBAU-CLS&HeQiS for BioAl-Manufacturing , Baoding, Hebei, China.

MeSH

AnimalsCOVID-19ChiropteraHumansMiddle East Respiratory Syndrome CoronavirusPhylogenyPneumoniaSevere acute respiratory syndrome-related coronavirusSARS-CoV-2Spike Glycoprotein, Coronavirus

Pub Type(s)

Journal Article

Language

eng

PubMed ID

32783700

Citation

Shahrajabian, Mohamad Hesam, et al. "Product of Natural Evolution (SARS, MERS, and SARS-CoV-2); Deadly Diseases, From SARS to SARS-CoV-2." Human Vaccines & Immunotherapeutics, vol. 17, no. 1, 2021, pp. 62-83.
Shahrajabian MH, Sun W, Cheng Q. Product of natural evolution (SARS, MERS, and SARS-CoV-2); deadly diseases, from SARS to SARS-CoV-2. Hum Vaccin Immunother. 2021;17(1):62-83.
Shahrajabian, M. H., Sun, W., & Cheng, Q. (2021). Product of natural evolution (SARS, MERS, and SARS-CoV-2); deadly diseases, from SARS to SARS-CoV-2. Human Vaccines & Immunotherapeutics, 17(1), 62-83. https://doi.org/10.1080/21645515.2020.1797369
Shahrajabian MH, Sun W, Cheng Q. Product of Natural Evolution (SARS, MERS, and SARS-CoV-2); Deadly Diseases, From SARS to SARS-CoV-2. Hum Vaccin Immunother. 2021 01 2;17(1):62-83. PubMed PMID: 32783700.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Product of natural evolution (SARS, MERS, and SARS-CoV-2); deadly diseases, from SARS to SARS-CoV-2. AU - Shahrajabian,Mohamad Hesam, AU - Sun,Wenli, AU - Cheng,Qi, Y1 - 2020/08/12/ PY - 2020/8/14/pubmed PY - 2021/3/2/medline PY - 2020/8/14/entrez KW - MERS KW - SARS KW - SARS-CoV-2 KW - coronaviruses KW - emerging diseases KW - pneumonia SP - 62 EP - 83 JF - Human vaccines & immunotherapeutics JO - Hum Vaccin Immunother VL - 17 IS - 1 N2 - SARS-CoV-2, the virus causing COVID-19, is a single-stranded RNA virus belonging to the order Nidovirales, family Coronaviridae, and subfamily Coronavirinae. SARS-CoV-2 entry to cellsis initiated by the binding of the viral spike protein (S) to its cellular receptor. The roles of S protein in receptor binding and membrane fusion makes it a prominent target for vaccine development. SARS-CoV-2 genome sequence analysis has shown that this virus belongs to the beta-coronavirus genus, which includes Bat SARS-like coronavirus, SARS-CoV and MERS-CoV. A vaccine should induce a balanced immune response to elicit protective immunity. In this review, we compare and contrast these three important CoV diseases and how they inform on vaccine development. SN - 2164-554X UR - https://www.unboundmedicine.com/medline/citation/32783700/Product_of_natural_evolution__SARS_MERS_and_SARS_CoV_2_ DB - PRIME DP - Unbound Medicine ER -